Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
| Distributed by / for | Rising Pharma Holdings, Inc., East Brunswick, NJ |
| NDC | 57237-018-30 |
| Full product label | Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC 57237-018-90) and c) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ |
| Recalling firm | Rising Pharma Holding, Inc. |
| Distribution | Nationwide. |
| Quantity | 122,925 bottles |
| Recall initiated | 2024-11-19 |
| Report date | 2024-12-11 |
| Recall completed | — |
| Recall number | D-0106-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Brunswick NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗